Corporate venture capitalists have long been considered second class citizens compared to their traditional VC counterparts.
No more.
A new report concludes that corporate VC activity in healthcare is not only rising in terms of quantity, but the type of the investors participating and their focus show a qualitative shift in how they spur innovation.
